ReviewJournal of immunology research2026
The Relationship Between CCN3 and Rheumatoid Arthritis and Its Potential Therapeutic Value.
Review in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Relationship Between CCN3 and Rheumatoid Arthritis and Its Potential Therapeutic Value.Journal of immunology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation, progressive joint destruction, and bone damage. Despite advances in disease-modifying antirheumatic drugs (DMARDs), unmet clinical needs arising from incomplete efficacy and safety concerns continue to drive the search for innovative therapeutic targets. Cellular communication network factor 3 (CCN3), a matricellular CCN family protein, is low in normal synovium but elevated in RA synovium and circulation, where it correlates with disease activity, anti-cyclic citrullinated peptide (anti-CCP) antibody titers, and IL-6. CCN3-associated effects may involve inflammatory-cell recruitment, fibroblast-like synoviocyte (FLS) activation and senescence, extracellular matrix (ECM) remodeling, cartilage degeneration, and osteoclastogenesis. Mechanistically, CCN3 may interact with RA-relevant NF-κB, Wnt/β-catenin, BMP/Smad, PI3K/Akt/mTOR, IL-6/JAK/STAT, Notch, and MAPK signaling networks. This review comprehensively examines the expression patterns, functional mechanisms, signaling pathways, and ongoing debates concerning CCN3 in RA and further explores its promise as a therapeutic target in preclinical research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.